Company intelligence / Profile preview
Brooklyn ImmunoTherapeutics, Inc.
Brooklyn, New York, United Statesbrooklynitx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. In a Phase 1b clinical trial in early stage breast cancer, IRX-2 was well-tolerated with no Grade 3 or 4 toxicities and showed encouraging signs of activity including upregulation of PD-L1.
- Therapeutic areas
- OncologyPulmonologyRare DiseasesHematology
- Modalities
- Cytokine-based therapyGene editing/cell therapymRNA cell engineering technology
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Factor BioscienceNovellusProvidence Cancer InstituteJohn Theurer Cancer CenterUniversity of Miami
Beyond the preview
Go deeper on Brooklyn ImmunoTherapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brooklyn ImmunoTherapeutics, Inc..